Core Insights - The article discusses the performance and investment potential of Sarepta Therapeutics (NASDAQ: SRPT), noting that the stock was trading near $160 per share nearly a year ago following a significant FDA approval [1]. Group 1 - Sarepta Therapeutics experienced a notable rise in stock price due to the FDA's expanded approval, which is a key factor in its investment appeal [1]. - The author emphasizes a focus on innovative companies in the biotech sector that are developing breakthrough therapies, indicating a strategic investment approach [1]. Group 2 - The article is part of a subscription marketplace service called Compounding Healthcare, which offers various resources for healthcare investors, including model portfolios and newsletters [1].